Biomarkers and genetic determinants of cardiac sarcoidosis : current status, the unmet needs and future perspectives

Bajec, Tine (avtor), Harlander, Matevž (avtor), Koren Pucelj, Nadja (avtor), Kassi, Mahwash (avtor), Poglajen, Gregor (avtor)

Sarcoidosis is a systemic disorder driven by genetic predisposition, environmental exposures, and immune dysregulation, resulting in the formation of noncaseating granulomas across multiple organs. In cardiac sarcoidosis (CS), immune cell infiltration of the myocardium, epicardium, and endocardium may lead to conduction disturbances, ventricular arrhythmias, and heart failure. While overt cardiac involvement was historically considered rare, affecting only 5% of sarcoidosis patients, the wider availability and improved sensitivity of contemporary cardiac imaging have revealed a substantially higher burden, with cardiac involvement reaching up to 55% in selected, systematically screened populations. Current diagnostic approaches for CS, including endomyocardial biopsy (EMB), cardiovascular magnetic resonance (CMR), and fluorine-18 fluorodeoxyglucose–positron emission tomography (FDG-PET), offer valuable insights but are restricted by high costs, invasiveness, and limited sensitivity and specificity. These challenges, together with the disproportionate contribution of cardiac involvement to sarcoidosis-related mortality, underscore the need for innovative, non-invasive, and widely accessible diagnostic strategies. Emerging evidence suggests that novel serum biomarkers and genomic studies hold promise for transforming the diagnostic landscape of CS. Biomarkers may provide accessible, cost-effective tools to complement established diagnostic methods, while genetic insights could identify individuals at higher risk for cardiac involvement and stratify patients based on disease phenotype. This review examines current evidence on serum biomarkers and genetic studies in CS diagnosis, identifies critical knowledge gaps, and proposes future directions aimed at advancing diagnostic precision and improving clinical outcomes.

• Jezik: Angleški jezik
• Ključne besede: biomarker, genetics, heart, sarcoidosis, therapy
• Vrsta gradiva: Članek v reviji
• Tipologija: 1.02 - Pregledni znanstveni članek
• Organizacija: MF - Medicinska fakulteta
• Status publikacije: Objavljeno
• Različica publikacije: Objavljena publikacija
• Leto izida: 2026
• Št. strani: 10 str.
• Številčenje: Vol. 13, art. 1754375
• PID: 20.500.12556/RUL-181249
• UDK: 616.1
• ISSN pri članku: 2297-055X
• DOI: 10.3389/fcvm.2026.1754375
• COBISS.SI-ID: 271877123
• Datum objave v RUL: 01.04.2026

Gradivo je del revije

• Naslov: Frontiers in cardiovascular medicine
• Skrajšan naslov: Front. cardiovasc. med.
• Založnik: Frontiers Media
• ISSN: 2297-055X
• COBISS.SI-ID: 523093273

Licence

• Licenca: CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
• Povezava: http://creativecommons.org/licenses/by/4.0/deed.sl
• Opis: To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Sekundarni jezik

• Jezik: Slovenski jezik
• Ključne besede: biološki označevalec, genetika, srce, sarkoidoza, terapija

Projekti

• Financer: ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
• Številka projekta: P3-0457
• Naslov: Nove strategije diagnostike in zdravljenja srčnega popuščanja